LAMAinDiab - Lisdexamphetamine Vs Methylphenidate for Pediatric Patients with ADHD and Type 1 Diabetes - a Randomized Cross-over Clinical Trial
Latest Information Update: 02 Dec 2024
Price :
$35 *
At a glance
- Drugs Lisdexamfetamine (Primary) ; Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder; Type 1 diabetes mellitus
- Focus Adverse reactions; Therapeutic Use
- Acronyms LAMAinDiab
- 28 Nov 2024 Status changed from not yet recruiting to recruiting.
- 06 Oct 2023 Planned End Date changed from 1 Jul 2026 to 1 Dec 2027.
- 06 Oct 2023 Planned primary completion date changed from 1 Jul 2026 to 1 Dec 2027.